Analysts Are Bullish on These Healthcare Stocks: Unity Biotechnology Inc (UBX), Alnylam Pharma (ALNY)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unity Biotechnology Inc (UBX) and Alnylam Pharma (ALNY) with bullish sentiments.

Unity Biotechnology Inc (UBX)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Unity Biotechnology Inc today and set a price target of $33. The company’s shares opened today at $10.26, close to its 52-week low of $9.55.

Syed noted:

“We spoke to UBX C-Suite this morning and the conclusion here, in our view, is that this 2Q19 dataset will likely require some dialogue once it’s out. It’s not necessarily a positive or negative in and of itself, but the cellular senescence field is just very new and the company is learning at the same time as investors on this one, so pinpointing the bogey here is incredibly difficult. That said, here is what we learned from our conversation.”

According to TipRanks.com, Syed is a 4-star analyst with an average return of 4.9% and a 56.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Wave Life Sciences, and Gilead Sciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Unity Biotechnology Inc with a $28.50 average price target.

See today’s analyst top recommended stocks >>

Alnylam Pharma (ALNY)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Alnylam Pharma today and set a price target of $135. The company’s shares opened today at $85.46.

Young said:

“. We are reiterating our Overweight rating and $135 price target. This morning Alnylam announced positive pivotal Ph3 data for givosiran (n=94), which they had previously guided to reading out this month. We think strong efficacy data supports filing in mid-2019 and approval in early 2020. We model ~ $475M in 2026 sales, and think they could get a broad label given clear benefits seen on attack rate and hospitalizations. We think positive data was expected after the interim, but strong efficacy underpins risk/benefit profile. Givosiran met the primary endpoint of reduction in annualized attack rate vs. placebo at 6 months, including hospitalizations.”

According to TipRanks.com, Young is a 4-star analyst with an average return of 8.0% and a 49.7% success rate. Young covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $121 average price target, a 41.6% upside from current levels. In a report released yesterday, Morgan Stanley also upgraded the stock to Buy with a $122 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts